Table 3. Efficacy endpoints.

		All patients diagnosed with G6PD deficiency by FST	Subgroup of patients with G6PD deficiency confirmed by genotyping	G6PD normal patients enrolled in the randomised trial
		PQ 8 weeks	PQ 8 weeks	Placebo	PQ7days	PQ14days
		N = 50	N = 31	N = 464	N = 935	N = 937
Incidence Rates per 1000 person years (95%CI)
	Total patient days of follow-up (days) [1]	15,613	10,235	138,712	278,655	285,652
1 Year	Symptomatic P. vivax parasitaemia	46.8 (11.7 − 187.1)	71.4 (17.9–285.4)	960 (830–1080)	180 (150–210)	160 (130–180)
	Any P. vivax parasitaemia	46.8 (11.7 − 187.1)	71.4 (17.9–285.4)	1320 (1150–1480)	230 (190–270)	190 (150–230)
	Any P. falciparum parasitaemia	70.2 (3.9–1263.3)	107.1 (6.1–1885.3)	100 (50–150)	150 (110–190)	100 (70–140)
	Parasitaemia due to any species	117.0 (29.9–457.0)	178.4 (46.8–680.6)	1420 (1250–1590)	380 (320–440)	300 (240–350)
Incidence Risks (95%CI)
Day 28	Any P. vivax parasitaemia	0%	0%	1.7% (0.8–3.6)	0.23% (0.06–0.93)	0.33% (0.10–1.00)
Day 42	Any P. vivax parasitaemia	0%	0%	7.9% (5.6–11.0)	0.87% (0.41–1.81)	0.82% (0.39–1.72)
1 Year	Symptomatic P. vivax parasitaemia	5.1% (1.3–18.9)	7.9% (2.0–28.1)	48.7% (43.4–54.4)	14.3% (11.8–17.3)	12.7% (10.2–15.8)
	Any P. vivax parasitaemia	5.1% (1.3–18.9)	7.9% (2.0–28.1)	58.40% (53.3–63.6)	16.0% (13.4–19.1)	14.8% (12.1–17.9)
	Any P. falciparum parasitaemia	2.1% (0.3–13.9)	3.2% (0.5–20.8)	11.4% (7.7–16.8)	8.67% (6.80–11.03)	7.22% (5.51–9.45)
	Parasitaemia due to any species	7.2% (2.4 − 20.9)	11.2% (3.7–31.0)	1.4% (1.3–1.6)	0.38% (0.32–0.44)	0.30% (0.24–0.35)